Page 102 - pfizervax
P. 102

PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines)
                   Protocol C4591001


                       •  The investigator or an authorized designee completes the CRFs.

                       •  Record any AEs that occur within the 48 hours after the blood draw as described in
                          Section 8.3.

                   8.11.2.6. Visit 6 – 24-Month Follow-up Visit: (714 to 742 Days After Visit 2)

                       •  Collect a blood sample (approximately 20 mL for participants ≥16 years of age and
                          approximately 10 mL for participants in the 12- to 15-year age stratum) for
                          immunogenicity testing.

                       •  Record details of any of the prohibited medications specified in Section 6.5.1
                          received by the participant if required for his or her clinical care.

                       •  For participants who are HIV-positive, record HIV viral load and CD4 count results
                          from the most recent test performed since Visit 5 (if any).

                       •  Collect the participant’s e-diary or assist the participant to remove the study
                          application from his or her own personal device.


                       •  Complete the source documents.

                       •  The investigator or an authorized designee completes the CRFs.

                       •  Record any AEs that occur within the 48 hours after the blood draw as described in
                          Section 8.3.

                   8.12. Unscheduled Visit for a Grade 3 or Suspected Grade 4 Reaction

                   If a Grade 3 local reaction (Section 8.2.2.2), systemic event (Section 8.2.2.3), or fever
                   (Section 8.2.2.4) is reported in the reactogenicity e-diary, a telephone contact should occur to
                   ascertain further details and determine whether a site visit is clinically indicated. If suspected
                   Grade 4 local reaction (Section 8.2.2.2), systemic event (Section 8.2.2.3), or fever
                   (Section 8.2.2.4) is reported in the reactogenicity e-diary, a telephone contact or site visit
                   should occur to confirm whether the event meets the criteria for Grade 4.

                   A site visit must be scheduled as soon as possible to assess the participant unless any of the
                   following is true:

                       •  The participant is unable to attend the unscheduled visit.


                       •  The local reaction/systemic event is no longer present at the time of the telephone
                          contact.

                       •  The participant or his/her parent(s)/legal guardian, as appropriate, recorded an
                          incorrect value in the reactogenicity e-diary (confirmation of a reactogenicity e-diary
                          data entry error).





                                                             Page 92
   97   98   99   100   101   102   103   104   105   106   107